There hasn't been too much in the news lately, but there was an article in Discover Magazine back in January (right before they took off). Basically if TRMS can continue the amazing progress they have thus far on inhibiting HIV, the sky is the limit for the stock. I believe the only drawback so far is that the treatment is a protein base, and must be injected twice a day. It couldn't hurt to sell now, but why?-gnilka
Best Of |
Favorites & Replies |
Start a New Board |
My Fool |
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Rat